Early investigational drugs that target epidermal growth factor receptors for the treatment of head and neck cancer

Bibliography

• Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014;64:9-29
   PubMed Web of Science ®Google Scholar
• Bose P, Brockton NT, Dort JC. Head and neck cancer: from anatomy to biology. Int J Cancer 2013;133:2013-23
   PubMed Web of Science ®Google Scholar
• Schmitz S, Ang KK, Vermorken J, et al. Targeted therapies for squamous cell carcinoma of the head and neck: current knowledge and future directions. Cancer Treat Rev 2014;40:390-404
   PubMed Web of Science ®Google Scholar
• Haddad RI, Shin DM. Recent advances in head and neck cancer. N Engl J Med 2008;359:1143-54
   PubMed Web of Science ®Google Scholar
• Cohen RB. Current challenges and clinical investigations of epidermal growth factor receptor (EGFR) - and ErbB family-targeted agents in the treatment of head and neck squamous cell carcinoma (HNSCC). Cancer Treat Rev 2014;40:567-77
   PubMed Web of Science ®Google Scholar
• Mak MP, William WN Jr. Targeting the epidermal growth factor receptor for head and neck cancer chemoprevention. Oral Oncol 2014; published online 9 January 2014; doi: 10.1016/j.oraloncology.2013.12.024
   Web of Science ®Google Scholar
• Roskoski R Jr. The ErbB/HER family of protein-tyrosine kinases and cancer. Pharmacol Res 2014;79:34-74
   PubMed Web of Science ®Google Scholar
• Yotsumoto F, Yagi H, Suzuki SO, et al. Validation of HB-EGF and amphiregulin as targets for human cancer therapy. Biochem Biophys Res Commun 2008;365:555-61
   PubMed Web of Science ®Google Scholar
• Zimmermann M, Zouhair A, Azria D, Ozsahin M. The epidermal growth factor receptor (EGFR) in head and neck cancer: its role and treatment implications. Radiat Oncol 2006;1:11
   PubMed Web of Science ®Google Scholar
• Kalyankrishna S, Grandis JR. Epidermal growth factor receptor biology in head and neck cancer. J Clin Oncol 2006;24:2666-72
   PubMed Web of Science ®Google Scholar
• Carpenter G, Cohen S. Epidermal growth factor. Annu Rev Biochem 1979;48:193-216
   PubMed Web of Science ®Google Scholar
• Grandis J, Tweardy D. Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. Cancer Res 1993;53:3579-84
   PubMed Web of Science ®Google Scholar
• Rubin Grandis J, Melhem MF, Barnes EL, Tweardy DJ. Quantitative immunohistochemical analysis of transforming growth factor-alpha and epidermal growth factor receptor in patients with squamous cell carcinoma of the head and neck. Cancer 1996;78:1284-92
   PubMed Web of Science ®Google Scholar
• Wheeler S, Siwak DR, Chai R, et al. Tumor epidermal growth factor receptor and EGFR PY1068 are independent prognostic indicators for head and neck squamous cell carcinoma. Clin Cancer Res 2012;18:2278-89
   PubMed Web of Science ®Google Scholar
• Gandhi MD, Agulnik M. Targeted treatment of head and neck squamous-cell carcinoma: potential of lapatinib. Onco Targets Ther 2014;7:245-51
   PubMed Web of Science ®Google Scholar
• Gillison ML, D’Souza G, Westra W, et al. Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers. J Natl Cancer Inst 2008;100:407-20
   PubMed Web of Science ®Google Scholar
• Goon PK, Stanley MA, Ebmeyer J, et al. HPV & head and neck cancer: a descriptive update. Head Neck Oncol 2009;1:36
   PubMedGoogle Scholar
• Kabolizadeh P, Kubicek GJ, Heron DE, et al. The role of cetuximab in the management of head and neck cancers. Expert Opin Biol Ther 2012;12:517-28
   PubMed Web of Science ®Google Scholar
• Li S, Schmitz KR, Jeffrey PD, et al. Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Cancer Cell 2005;7:301-11
   PubMed Web of Science ®Google Scholar
• Chen DJ, Nirodi CS. The epidermal growth factor receptor: a role in repair of radiation-induced DNA damage. Clin Cancer Res 2007;13:6555-60
   PubMed Web of Science ®Google Scholar
• Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006;354:567-78
   PubMed Web of Science ®Google Scholar
• Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 2010;11:21-8
   PubMed Web of Science ®Google Scholar
• Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008;359:1116-27
   PubMed Web of Science ®Google Scholar
• Vermorken JB, Remenar E, Hitt R, et al. Platinum-based chemotherapy (CT) plus cetuximab in recurrent or metastatic squamous cel carcinoma of the head and neck cancer (R/M-SCCHN): 5-year follow-up data for the extreme trial. J Clin Oncol 2014;32(5S):abstract 6021
   Google Scholar
• Lefebvre JL, Pointreau Y, Rolland F, et al. Induction chemotherapy followed by either chemoradiotherapy or bioradiotherapy for larynx preservation: the TREMPLIN randomized phase II study. J Clin Oncol 2013;31:853-9
   PubMed Web of Science ®Google Scholar
• Dietz A, Flentje M, Hagen R, et al. Induction chemotherapy (IC) docetaxel (T), cisplatin (P), 5-fluorouracil (F) (TPF), or TP followed by concomitant boost radiotherapy (R) with or without cetuximab (E) for functional organ preservation (FOP) of resectable laryngeal and hypopharyngeal cancer (LHSCC): first results of the phase II randomized DeLOS-II study. J Clin Oncol 2014;32(5S):abstract 6016
   Google Scholar
• Ang KK, Zhang Q, Rosenthal DI, et al. A randomized phase III trial (RTOG 0522) of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III-IV head and neck squamous cell carcinomas (HNC). J Clin Oncol 2011;29(15S):abstract 5500
   Google Scholar
• Harari PM, Harris J, Kies MS, et al. Postoperative chemoradiotherapy and cetuximab for high-risk squamous cell carcinoma of the head and neck: Radiation Therapy Oncology Group RTOG-0234. J Clin Oncol 2014. [Epub ahead of print]
   Google Scholar
• Bar-Ad V, Zhang Q, Harrari PM, et al. The correlation between the severity of cetuximab-induced rash and clinical outcome for patients with head and neck carcinoma treated with chemoradiotherapy (CRT) plus cetuximab: the RTOG experience. J Clin Oncol 2014;32(5S):abstract 6025
   Google Scholar
• Ghi MG, Paccagnella A, Ferrari D, et al. Concomitant chemoradiation (CRT) or cetuximab/RT (CET/RT) versus induction docetaxel/cisplatin/5-fluorouracil (TPF) followed by CRT or CET/RT in patients with locally advanced squamous cell carcinoma of head and neck (LASCCHN): a randomized phase III factorial study (NCT01086826). J Clin Oncol 2014;32(5S):abstract 6004
   Google Scholar
• Koutcher L, Sherman E, Fury M, et al. Concurrent cisplatin and radiation versus cetuximab and radiation for locally advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys 2011;81:915-22
   PubMed Web of Science ®Google Scholar
• Riaz N, Sherman E, Koutcher L, et al. Concurrent chemoradiotherapy with cisplatin versus cetuximab for squamous cell carcinoma of the head and neck. Am J Clin Oncol 2014. [Epub ahead of print]
   Google Scholar
• Caudell JJ, Sawrie SM, Spencer SA, et al. Locoregionally advanced head and neck cancer treated with primary radiotherapy: a comparison of the addition of cetuximab or chemotherapy and the impact of protocol treatment. Int J Radiat Oncol Biol Phys 2008;71:676-81
   PubMed Web of Science ®Google Scholar
• Barni S, Coinu A, Borgonovo K, et al. Cisplatin versus cetuximab plus concomitant radiotherapy in locally advanced head and neck cancer: a meta-analysis of published trials. J Clin Oncol 2014;32(5S):abstract 6014
   Google Scholar
• Day KE, Sweeny L, Kulbersh B, et al. Preclinical comparison of near-infrared-labeled cetuximab and panitumumab for optical imaging of head and neck squamous cell carcinoma. Mol Imaging Biol 2013;15:722-9
   PubMed Web of Science ®Google Scholar
• Yang XD, Jia XC, Corvalan JR, et al. Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy. Crit Rev Oncol Hematol 2001;38:17-23
   PubMed Web of Science ®Google Scholar
• Foon KA, Yang XD, Weiner LM, et al. Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody. Int J Radiat Oncol Biol Phys 2004;58:984-90
   PubMed Web of Science ®Google Scholar
• Wirth LJ, Allen AM, Posner MR, et al. Phase I dose-finding study of paclitaxel with panitumumab, carboplatin and intensity-modulated radiotherapy in patients with locally advanced squamous cell cancer of the head and neck. Ann Oncol 2010;21:342-7
   PubMed Web of Science ®Google Scholar
• Wirth LJ, Dakhil SR, Kornek G, et al. PARTNER: a randomized phase II study of docetaxel/cisplatin (doc/cis) chemotherapy with or without panitumumab (pmab) as first-line treatment (tx) for recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN). J Clin Oncol 2013;31(Suppl):abstract 6029
   Google Scholar
• Vermorken JB, Stöhlmacher-Williams J, Davidenko I, et al. Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial. Lancet Oncol 2013;14:697-710
   PubMed Web of Science ®Google Scholar
• Stoehlmacher-Williams J, Villanueva C, Foa P, et al. Safety and efficacy of panitumumab (pmab) in HPV-positive (+) and HPV-negative (-) recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): analysis of the global phase III SPECTRUM trial. J Clin Oncol 2012;20(15S):abstract 5504
   Google Scholar
• Giralt J, Fortin A, Mesia R, et al. A phase II, randomized trial (CONCERT-1) of chemoradiotherapy (CRT) with or without panitumumab (pmab) in patients (pts) with unresected, locally advanced squamous cell carcinoma of the head and neck (LASCCHN). J Clin Oncol 2012;30:abstract 5502
   Google Scholar
• Giralt J, Trigo JM, Nuyts S, et al. Phase 2, randomized trial (Concert-2) of panitumumab (Pmab) plus radiotherapy (PRT) compared with chemotherapy (CRT) in patients (pts) with unresected locally advanced squamous cell carcinoma of the head and neck (LASCCHN) [abstract 10160]. Ann Oncol 2012;23:ix334-47
   Google Scholar
• Ferris RL, Schmitt NC, Heron DE, et al. Phase II trial of radiotherapy (RT) with concurrent cisplatin (C) plus panitumumab (pmAb) for patients (pts) with high-risk, resected head and neck cancer (HNC). J Clin Oncol 2014;32(5S):abstract 6090
   Google Scholar
• Schick U, Gujral DM, Richards TM, et al. Zalutumumab in head and neck cancer. Expert Opin Biol Ther 2012;12:119-25
   PubMed Web of Science ®Google Scholar
• Lammerts van Bueren JJ, Bleeker WK, Brännström A, et al. The antibody zalutumumab inhibits epidermal growth factor receptor signaling by limiting intra- and intermolecular flexibility. Proc Natl Acad Sci USA 2008;105:6109-14
   PubMed Web of Science ®Google Scholar
• Bastholt L, Specht L, Jensen K, et al. Phase I/II clinical and pharmacokinetic study evaluating a fully human monoclonal antibody against EGFr (HuMax-EGFr) in patients with advanced squamous cell carcinoma of the head and neck. Radiother Oncol 2007;85:24-8
   PubMed Web of Science ®Google Scholar
• Machiels JP, Subramanian S, Ruzsa A, et al. Zalutumumab plus best supportive care versus best supportive care alone in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinum-based chemotherapy: an open-label, randomised phase 3 trial. Lancet Oncol 2011;12:333-43
   PubMed Web of Science ®Google Scholar
• Crombet-Ramos T, Rak J, Pérez R, Viloria-Petit A. Antiproliferative, antiangiogenic and proapoptotic activity of h-R3: a humanized anti-EGFR antibody. Int J Cancer 2002;101:567-75
   PubMed Web of Science ®Google Scholar
• Crombet T, Osorio M, Cruz T, et al. Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients. J Clin Oncol 2004;22:1646-54
   PubMed Web of Science ®Google Scholar
• Allan DG. Nimotuzumab: evidence of clinical benefit without rash. Oncologist 2005;10:760-1
   PubMed Web of Science ®Google Scholar
• Rodríguez MO, Rivero TC, del Castillo Bahi R, et al. Nimotuzumab plus radiotherapy for unresectable squamous-cell carcinoma of the head and neck. Cancer Biol Ther 2010;9:343-9
   PubMed Web of Science ®Google Scholar
• González JE, Barquinero JF, Lee M, et al. Radiosensitization induced by the anti-epidermal growth factor receptor monoclonal antibodies cetuximab and nimotuzumab in A431 cells. Cancer Biol Ther 2012;13:71-6
   PubMed Web of Science ®Google Scholar
• Cleary JM, Yee K-CL, Azad N, et al. A phase 1 study of ABT-806, a 40 humanized recombinant anti-EGFR monoclonal antibody, in patients with advanced solid tumors. Cancer Res 2012;72(8 Suppl):abstract 2506
   Google Scholar
• Gan HK, Burge ME, Solomon BJ, et al. A phase I and biodistribution study of ABT-806i, an [111] indium-labeled conjugate of the tumor-specific anti-EGFR antibody ABT-806. J Clin Oncol 2013;31(15S):abstract 2520
   Google Scholar
• Paz-Ares LG, Gomez-Roca C, Delord JP, et al. Phase I pharmacokinetic and pharmacodynamic dose-escalation study of RG7160 (GA201), the first glycoengineered monoclonal antibody against the epidermal growth factor receptor, in patients with advanced solid tumors. J Clin Oncol 2011;29:3783-90
   PubMedGoogle Scholar
• Brehmer D, Greff Z, Godl K, et al. Cellular targets of gefitinib. Cancer Res 2005;65:379-82
   PubMed Web of Science ®Google Scholar
• Cohen EE, Rosen F, Stadler WM, et al. Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 2003;21:1980-7
   PubMed Web of Science ®Google Scholar
• Cohen EE, Kane MA, List MA, et al. Phase II trial of gefitinib 250 mg daily in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. Clin Cancer Res 2005;11:8418-24
   PubMed Web of Science ®Google Scholar
• Caponigro F, Romano C, Milano A, et al. A phase I/II trial of gefitinib and radiotherapy in patients with locally advanced inoperable squamous cell carcinoma of the head and neck. Anticancer Drugs 2008;19:739-44
   PubMed Web of Science ®Google Scholar
• Hainsworth JD, Spigel DR, Burris HA III, et al. Neoadjuvant chemotherapy/gefitinib followed by concurrent chemotherapy/radiation therapy/gefitinib for patients with locally advanced squamous carcinoma of the head and neck. Cancer 2009;115:2138-46
   PubMed Web of Science ®Google Scholar
• Grégoire V, Hamoir M, Chen C, et al. Gefitinib plus cisplatin and radiotherapy in previously untreated head and neck squamous cell carcinoma: a phase II, randomized, double-blind, placebo-controlled study. Radiother Oncol 2011;100:62-9
   PubMed Web of Science ®Google Scholar
• Stewart JS, Cohen EE, Licitra L, et al. Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck. J Clin Oncol 2009;27:1864-71
   PubMed Web of Science ®Google Scholar
• Argiris A, Ghebremichael M, Gilbert J, et al. A phase III randomized, placebo-controlled trial of docetaxel with or without gefitinib in recurrent or metastatic head and neck cancer: an eastern cooperative oncology group trial. J Clin Oncol 2013;31:1405-14
   PubMed Web of Science ®Google Scholar
• Fung C, Grandis JR. Emerging drugs to treat squamous cell carcinomas of the head and neck. Expert Opin Emerg Drugs 2010;15:355-73
   PubMed Web of Science ®Google Scholar
• Ranson M. Epidermal growth factor receptor tyrosine kinase inhibitors. Br J Cancer 2004;90:2250-5
   PubMed Web of Science ®Google Scholar
• Soulieres D, Senzer NN, Vokes EE, et al. Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol 2004;22:77-85
   PubMed Web of Science ®Google Scholar
• Chinnaiyan P, Huang S, Vallabhaneni G, et al. Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva). Cancer Res 2005;65:3328-35
   PubMed Web of Science ®Google Scholar
• Siu LL, Soulieres D, Chen EX, et al. Princess Margaret Hospital Phase II Consortium, National Cancer Institute of Canada Clinical Trials Group Study. Phase I/II trial of erlotinib and cisplatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: a Princess Margaret Hospital phase II consortium and National Cancer Institute of Canada Clinical Trials Group Study. J Clin Oncol 2007;25:2178-83
   PubMed Web of Science ®Google Scholar
• Herchenhorn D, Dias FL, Viegas CM, et al. Phase I/II study of erlotinib combined with cisplatin and radiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 2010;78:696-702
   PubMed Web of Science ®Google Scholar
• Heath CH, Deep NL, Nabell L, et al. Phase 1 study of erlotinib plus radiation therapy in patients with advanced cutaneous squamous cell carcinoma. Int J Radiat Oncol Biol Phys 2013;85:1275-81
   PubMed Web of Science ®Google Scholar
• Arias de la Vega F, Contreras J, de Las Heras M, et al. Erlotinib and chemoradiation in patients with surgically resected locally advanced squamous cell carcinoma of the head and neck: a GICOR phase I trial. Ann Oncol 2012;23:1005-9
   PubMed Web of Science ®Google Scholar
• Martins RG, Parvathaneni U, Bauman JE, et al. Cisplatin and radiotherapy with or without erlotinib in locally advanced squamous cell carcinoma of the head and neck: a randomized phase II trial. J Clin Oncol 2013;31:1415-21
   PubMed Web of Science ®Google Scholar
• Savvides P, Ayyappan S, Yao M, et al. Docetaxel (DOC) with concurrent radiation (CRT) and bevacizumab (BEV) or erlotinib (ERL) for locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN). J Clin Oncol 2014;32(5S):abstract 6070
   Google Scholar
• Medina PJ, Goodin S. Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases. Clin Ther 2008;30:1426-47
   PubMed Web of Science ®Google Scholar
• Kondo N, Tsukuda M, Ishiguro Y, et al. Antitumor effects of lapatinib (GW572016), a dual inhibitor of EGFR and HER-2, in combination with cisplatin or paclitaxel on head and neck squamous cell carcinoma. Oncol Rep 2010;23:957-63
   PubMed Web of Science ®Google Scholar
• Xia W, Mullin RJ, Keith BR, et al. Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways. Oncogene 2002;21:6255-63
   PubMed Web of Science ®Google Scholar
• Rusnak DW, Lackey K, Affleck K, et al. The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. Mol Cancer Ther 2001;1:85-94
   PubMed Web of Science ®Google Scholar
• Burris HA III, Hurwitz HI, Dees EC, et al. Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. J Clin Oncol 2005;23:5305-13
   PubMed Web of Science ®Google Scholar
• Harrington KJ, El-Hariry IA, Holford CS, et al. Phase I study of lapatinib in combination with chemoradiation in patients with locally advanced squamous cell carcinoma of the head and neck. J Clin Oncol 2009;27:1100-7
   PubMed Web of Science ®Google Scholar
• Harrington K, Berrier A, Robinson M, et al. Randomised Phase II study of oral lapatinib combined with chemoradiotherapy in patients with advanced squamous cell carcinoma of the head and neck: rationale for future randomised trials in human papilloma virus-negative disease. Eur J Cancer 2013;49:1609-18
   PubMed Web of Science ®Google Scholar
• Weiss J, Hayes DN, Algazy K, et al. Combination lapatinib and capecitabine in advanced, incurable squamous cell carcinoma of the head and neck (SCCHN). J Clin Oncol 2013;31:abstract 6094
   Google Scholar
• Del Campo JM, Hitt R, Sebastian P, et al. Effects of lapatinib monotherapy: results of a randomised phase II study in therapy-naive patients with locally advanced squamous cell carcinoma of the head and neck. Br J Cancer 2011;105:618-27
   PubMed Web of Science ®Google Scholar
• De Souza JA, Davis DW, Zhang Y, et al. A phase II study of lapatinib in recurrent/metastatic squamous cell carcinoma of the head and neck. Clin Cancer Res 2012;18:2336-43
   PubMed Web of Science ®Google Scholar
• Lalami Y, Specenier PM, Awada A, et al. EORTC 24051: unexpected side effects in a phase I study of TPF induction chemotherapy followed by chemoradiation with lapatinib, a dual EGFR/ErbB2 inhibitor, in patients with locally advanced resectable larynx and hypopharynx squamous cell carcinoma. Radiother Oncol 2012;105:238-40
   PubMed Web of Science ®Google Scholar
• Harrington KJ, Temam S, D’Cruz A, et al. Final analysis: a randomized, blinded, placebo-controlled phase III study of adjuvant postoperative lapatinib (L) with concurrent chemotherapy and radiation therapy (CH-RT) in high-risk patients with squamous cell carcinoma of the head and neck (SCCHN). J Clin Oncol 2014;32(5S):abstract 6005
   Google Scholar
• Solca F, Dahl G, Zoephel A, et al. Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker. J Pharmacol Exp Ther 2012;343:342-50
   PubMed Web of Science ®Google Scholar
• Schütze C, Dörfler A, Eicheler W, et al. Combination of EGFR/HER2 tyrosine kinase inhibition by BIBW 2992 and BIBW 2669 with irradiation in FaDu human squamous cell carcinoma. Strahlenther Onkol 2007;183:256-64
   PubMed Web of Science ®Google Scholar
• Yap TA, Vidal L, Adam J, et al. Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors. J Clin Oncol 2010;28:3965-72
   PubMed Web of Science ®Google Scholar
• Seiwert TY, Fayette J, Cupissol D, et al. A randomized, open-label, phase II study of afatinib versus cetuximab in recurrent/metastatic head and neck squamous cell carcinoma (HNSCC). Ann Oncol 2012;23(Suppl 11):xi35-6
   Google Scholar
• Cupissol D, Seiwert TY, Fayette J, et al. A randomized, open-label, phase II study of afatinib versus cetuximab in patients (pts) with recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): analysis of stage 2 (S2) following crossover. J Clin Oncol 2013;31:abstract 6001
   Google Scholar
• Gonzales AJ, Hook KE, Althaus IW, et al. Antitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor. Mol Cancer Ther 2008;7:1880-9
   PubMed Web of Science ®Google Scholar
• Engelman JA, Zejnullahu K, Gale CM, et al. PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib. Cancer Res 2007;67:11924-32
   PubMed Web of Science ®Google Scholar
• Jänne PA, Boss DS, Camidge DR, et al. Phase I dose-escalation study of the pan-HER inhibitor, PF299804, in patients with advanced malignant solid tumors. Clin Cancer Res 2011;17:1131-9
   PubMed Web of Science ®Google Scholar
• Abdul Razak AR, Soulières D, Laurie SA, et al. A phase II trial of dacomitinib, an oral pan-human EGF receptor (HER) inhibitor, as first-line treatment in recurrent and/or metastatic squamous-cell carcinoma of the head and neck. Ann Oncol 2013;24:761-9
   PubMed Web of Science ®Google Scholar
• Audet ML, Allo G, Weng X, et al. Evaluation of potential predictive markers of efficacy of dacomitinib in patients (pts) with recurrent/metastatic SCCHN from a phase II trial. J Clin Oncol 2013;31:abstract 6041
   Google Scholar
• Ather F, Hamidi H, Fejzo MS, et al. An irreversible Pan-ErbB inhibitor significantly abrogates growth in head and neck cancer models that exhibit low response to cetuximab. PLoS One 2013;8(2):e56112
   PubMedGoogle Scholar
• Schaefer G, Haber L, Crocker LM, et al. A two-in-one antibody against HER3 and EGFR has superior inhibitory activity compared with monospecific antibodies. Cancer Cell 2011;20:472-86
   PubMed Web of Science ®Google Scholar
• Huang S, Li C, Armstrong EA, et al. Dual targeting of EGFR and HER3 with MEHD7945A overcomes acquired resistance to EGFR inhibitors and radiation. Cancer Res 2013;73:824-33
   PubMed Web of Science ®Google Scholar
• Li C, Huang S, Armstrong EA, et al. MEHD7945A, a dual specific antibody against EGFR and HER3, augments radiation response in head and neck squamous cell carcinoma. In: Proceedings of the 103rd Annual meeting of the American Association for Cancer Research; 2012. abstract 2721
   Google Scholar
• Skartved NJ, Jacobsen HJ, Pedersen MW, et al. Preclinical pharmacokinetics and safety of Sym004: a synergistic antibody mixture directed against epidermal growth factor receptor. Clin Cancer Res 2011;17:5962-72
   PubMed Web of Science ®Google Scholar
• Pedersen MW, Jacobsen HJ, Koefoed K, et al. Sym004: a novel synergistic anti-epidermal growth factor receptor antibody mixture with superior anticancer efficacy. Cancer Res 2010;70:588-97
   PubMed Web of Science ®Google Scholar
• Iida M, Brand TM, Starr MM, et al. Sym004, a novel EGFR antibody mixture, can overcome acquired resistance to cetuximab. Neoplasia 2013;15:1196-206
   PubMed Web of Science ®Google Scholar
• Huang S, Peet CR, Saker J, et al. Sym004, a novel anti-EGFR antibody mixture, augments radiation response in human lung and head and neck cancers. Mol Cancer Ther 2013;12:2772-81
   PubMed Web of Science ®Google Scholar
• Wheeler DL, Dunn EF, Harari PM. Understanding resistance to EGFR inhibitors-impact on future treatment strategies. Nat Rev Clin Oncol 2010;7:493-507
   PubMed Web of Science ®Google Scholar
• Krumbach R, Schuler J, Hofmann M, et al. Primary resistance to cetuximab in a panel of patient-derived tumour xenograft models: activation of MET as one mechanism for drug resistance. Eur J Cancer 2011;47:1231-43
   PubMed Web of Science ®Google Scholar
• Rebucci M, Peixoto P, Dewitte A, et al. Mechanisms underlying resistance to cetuximab in the HNSCC cell line: role of AKT inhibition in bypassing this resistance. Int J Oncol 2011;38:189-200
   PubMed Web of Science ®Google Scholar
• Yonesaka K, Zejnullahu K, Okamoto I, et al. Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab. Sci Transl Med 2011;3:99ra86
   PubMed Web of Science ®Google Scholar
• Erjala K, Sundvall M, Junttila TT, et al. Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells. Clin Cancer Res 2006;12:4103-11
   PubMed Web of Science ®Google Scholar
• Rabinowits G, Haddad RI. Overcoming resistance to EGFR inhibitor in head and neck cancer: a review of the literature. Oral Oncol 2012;48:1085-9
   PubMed Web of Science ®Google Scholar
• Argiris A, Kotsakis AP, Hoang T, et al. Cetuximab and bevacizumab: preclinical data and phase II trial in recurrent or metastatic squamous cell carcinoma of the head and neck. Ann Oncol 2013;24:220-5
   PubMed Web of Science ®Google Scholar
• Cohen EE, Davis DW, Karrison TG, et al. Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study. Lancet Oncol 2009;10:247-57
   PubMed Web of Science ®Google Scholar
• Roda JM, Joshi T, Butchar JP, et al. The activation of natural killer cell effector functions by cetuximab-coated, epidermal growth factor receptor positive tumor cells is enhanced by cytokines. Clin Cancer Res 2007;13:6419-28
   PubMed Web of Science ®Google Scholar
• Wu L, Parton A, Lu L, et al. Lenalidomide enhances antibody-dependent cellular cytotoxicity of solid tumor cells in vitro: influence of host immune and tumor markers. Cancer Immunol Immunother 2011;60:61-73
   PubMedGoogle Scholar
• Lee P, Alvarez RH, Melichar B, et al. Phase I/II study of the investigational aurora A kinase (AAK) inhibitor MLN8237 (alisertib) in patients (pts) with non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), breast cancer (BrC), head/neck cancer (H&N), and gastroesophageal (GE) adenocarcinoma: preliminary phase II results. J Clin Oncol 2012;30(Suppl):abstract 3010
   Google Scholar
• Lu H, Dietsch GN, Matthews MA, et al. VTX-2337 is a novel TLR8 agonist that activates NK cells and augments ADCC. Clin Cancer Res 2012;18:499-509
   PubMed Web of Science ®Google Scholar
• Jimeno A, Kulesza P, Wheelhouse J, et al. Dual EGFR and mTOR targeting in squamous cell carcinoma models, and development of early markers of efficacy. Br J Cancer 2007;96:952-9
   PubMed Web of Science ®Google Scholar
• Bozec A, Etienne-Grimaldi MC, Fischel JL, et al. The mTOR-targeting drug temsirolimus enhances the growth-inhibiting effects of the cetuximab-bevacizumab-irradiation combination on head and neck cancer xenografts. Oral Oncol 2011;47:340-4
   Google Scholar
• Li C, Iida M, Dunn EF, Wheeler DL. Dasatinib blocks cetuximab- and radiation- induced nuclear translocation of the epidermal growth factor receptor in head and neck squamous cell carcinoma. Radiother Oncol 2010;97:330-7
   PubMed Web of Science ®Google Scholar
• Bauman JE, Duvvuri U, Gooding WE, et al. Erlotinib, dasatinib, erlotinib-dasatinib versus placebo: a randomized, double-blind window study in operable head and neck squamous cell carcinoma (HNSCC). J Clin Oncol 2014;32(5S):abstract 6033
   Google Scholar
• Ihle NT, Paine-Murrieta G, Berggren MI, et al. The phosphatidylinositol-3-kinase inhibitor PX-866 overcomes resistance to the epidermal growth factor receptor inhibitor gefitinib in A-549 human non-small cell lung cancer xenografts. Mol Cancer Ther 2005;4:1349-57
   PubMed Web of Science ®Google Scholar
• Psyrri A, Lee JW, Pectasides E, et al. Prognostic biomarkers in phase II trial of cetuximab-containing induction and chemoradiation in resectable HNSCC: eastern Cooperative Oncology Group E2303. Clin Cancer Res 2014;20:3023-32
   PubMed Web of Science ®Google Scholar
• Weidhaas JB, Harris J, Axelrod R, et al. The KRAS-variant and cetuximab response in RTOG 0522. J Clin Oncol 2014;32(5S):abstract 6000
   Google Scholar
• Kreimer AR, Clifford GM, Boyle P, Franceschi S. Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol Biomarkers 2005;14:467-75
   PubMed Web of Science ®Google Scholar
• Ang KK, Harris J, Wheeler R, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 2010;363:24-35
   PubMed Web of Science ®Google Scholar
• Vermorken JB, Psyrri A, Mesía R, et al. Impact of tumor HPV status on outcome in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck receiving chemotherapy with or without cetuximab: retrospective analysis of the phase III EXTREME trial. Ann Oncol 2014;25:801-7
   PubMed Web of Science ®Google Scholar
• Rosenthal DI, Harari PM, Giralt J, et al. Impact of p16 status on the results of the phase III cetuximab (cet)/radiotherapy (RT). J Clin Oncol 2014;32(5S):abstract 6001
   Google Scholar
• Califano JA, Ferris RL, Epstein JB, et al. A phase II trial of cetuximab in high-risk premalignant lesions of the upper aerodigestive tract. J Clin Oncol 2012;30(Suppl):abstract 5528
   Google Scholar
• William WN, Papadimitrakopoulou V, Lee JJ, et al. Randomized placebo-controlled trial (RCT) of erlotinib for prevention of oral cancer (EPOC). J Clin Oncol 2014;32(5S):abstract 6007
   Google Scholar
• Shin DM, Zhang H, Saba NF, et al. Chemoprevention of head and neck cancer by simultaneous blocking of epidermal growth factor receptor and cyclooxygenase-2 signaling pathways: preclinical and clinical studies. Clin Cancer Res 2013;19:1244-56
   PubMed Web of Science ®Google Scholar
• Saba NF, Hurwitz SJ, Kono SA, et al. Chemoprevention of head and neck cancer with celecoxib and erlotinib: results of a phase Ib and pharmacokinetic study. Cancer Prev Res (Phila) 2014;7:283-91
   PubMed Web of Science ®Google Scholar
• Gross ND, Bauman JE, Gooding WE, et al. Erlotinib, erlotinib-sulindac versus placebo: a randomized, double-blind, placebo-controlled window trial in operable head and neck cancer. Clin Cancer Res 2014;20:3289-98
   PubMed Web of Science ®Google Scholar
• Rosenthal EL, Chung TK, Carroll WR, et al. Assessment of erlotinib as adjuvant chemoprevention in high-risk head and neck cancer patients. Ann Surg Oncol 2014. [Epub ahead of print]
   Web of Science ®Google Scholar
• Pfister DG, Ang KK, Brizel D, et al. Head and neck cancers, version 2.2013. Featured updates to the NCCN guidelines. J Natl Compr Canc Netw 2013;11:917-23
   PubMed Web of Science ®Google Scholar
• Cooper JS, Pajak TF, Forastiere AA, et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 2004;350:1937-44
   PubMed Web of Science ®Google Scholar
• Bernier J, Domenge C, Ozsahin M, et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 2004;350:1945-52
   PubMed Web of Science ®Google Scholar
• Pignon JP, Le Maitre A, Maillard E, Bourhis J; MACH-NC Collaborative Group. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol 2009;92:4-14
   PubMed Web of Science ®Google Scholar
• Lefebvre JL, Chevalier D, Luboinski B, et al. Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer phase III trial. J Natl Cancer Inst 1996;88:890-9
   PubMed Web of Science ®Google Scholar
• Forastiere AA, Goepfert H, Maor M, et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 2003;349:2091-8
   PubMed Web of Science ®Google Scholar
• Forastiere AA, Zhang Q, Weber RS, et al. Long-term results of RTOG 91-11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer. J Clin Oncol 2013;31:845-52
   PubMed Web of Science ®Google Scholar
• Vermorken JB, Remenar E, van Herpen C, et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med 2007;357:1695-704
   PubMed Web of Science ®Google Scholar
• Posner MR, Hershock DM, Blajman CR, et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 2007;357:1705-15
   PubMed Web of Science ®Google Scholar
• Lorch JH, Goloubeva O, Haddad RI, et al. Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial. Lancet Oncol 2011;12:153-9
   PubMed Web of Science ®Google Scholar
• Pointreau Y, Garaud P, Chapet S, et al. Randomized trial of induction chemotherapy with cisplatin and 5-fluorouracil with or without docetaxel for larynx preservation. J Natl Cancer Inst 2009;101:498-506
   PubMed Web of Science ®Google Scholar
• Liberatoscioli C, Langendijk JA, Van Herpen C, et al. EORTC 22071-24071: randomized, phase III trial of EGFR-antibody combined with adjuvant chemoradiation for patients with head and neck squamous cell carcinoma (HNSCC) of high risk of recurrence. J Clin Oncol 2011;29(Suppl):abstract TPS197
   Google Scholar
• Peyrade F, Righini C, Gal J, et al. Adjuvant radiotherapy (RDT) plus cisplatinum (Cis) and cetuximab (Cet) in resected head and neck squamous cell carcinoma. J Clin Oncol 2014;32(5S):abstract 6042
   Google Scholar